Shares of medication company Viatris (NASDAQ:VTRS) jumped 3% in the morning session after it received approval from the U.S.

Venofer was approved in the U.S. in 2000. It was developed by Vifor Pharma, which is now part of CSL Ltd. American Regent, a unit of Daiichi Sankyo, manufactures and sells it in the U.S. under a ...

Viatris (NASDAQ:VTRS) announced on Monday that the U.S. FDA has approved its Iron Sucrose Injection, USP, as a generic ...

Viatris Inc (NASDAQ:VTRS) saw its stock increase by 2.6% after the U.S. Food and Drug Administration approved its Iron ...

Investing.com -- Viatris Inc (NASDAQ: VTRS) stock rose 2.6% following the U.S. Food and Drug Administration’s approval of the company’s Iron Sucrose Injection, USP, the first generic version of ...

Medication company Viatris (NASDAQ:VTRS) will be reporting earnings this Thursday before market open. Here’s what investors ...

Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and weak R&D. Read more on why I rate VTRS a Hold.

CANONSBURG, Pa. (AP) — CANONSBURG, Pa. (AP) — Viatris Inc (VTRS) on Thursday reported a loss of $4.6 million in its second quarter. The Canonsburg, Pennsylvania-based company said it had a loss of ...

A global healthcare company, Viatris, with a mission to empower people worldwide to live healthier at every stage of life, has launched its EmpowerED for Life ...

Viatris Inc. closed 31.66% below its 52-week high of $13.55, which the company reached on November 25th.

Viatris (NASDAQ: VTRS) started trading publicly via a spinoff-merger. Ever since, the stock has been underperforming due to selling pressure.

If Viatris could sell generic versions of Wegovy and Ozempic, it'd be a major driver of new top-line growth. Sales of Ozempic brought in more than $3 billion for Novo Nordisk in the most recent ...